Key Drivers
- Strong cash
- Low leverage
- High multiples
AIAI Summary
Trupanion has shifted from a pure subscriber-growth story to a cash-generative, margin-management investment where the stock's upside now hinges on sustaining mid-teens subscription margins and converting a majority of incremental AOI into durable net income rather than on top-line growth alone. Investors should watch for multi-quarter margin retention and >50% AOI-to-net-income conversion (or conversely accelerating veterinary inflation/receivables stress) as the decisive trigger for rerating or downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash
- •Low leverage
- •High multiples
TRUP combines strong liquidity and cash generation with low leverage but delivers weak current profitability and modest returns while trading at rich multiples and carrying large receivables/deferred revenue that tie up capital.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near-term support
- •Resistance cluster
Over the last month TRUP moved down from $29.06 to $26.21, sitting just below its ~$26.53 last-month SMA with support at $24.74 and resistance clustered at $28.0–$29.1, maintaining a short-term bearish bias unless it reclaims that band.
Sharp decline from ~$36.61 in
Sentiment & News
Key News Insights:
- •Pricing-led growth
- •Margin expansion
- •Large market runway
Trupanion is pushing for profitable 2026 growth led by pricing, increased headcount and tech-driven customer acquisition, margin expansion, investor outreach, and strategic partnerships, while industry medical-cost pressures remain a key risk.
Expect upward momentum for TRUP from stronger margins and subscription growth, but monitor medical-cost inflation as a potential near-term headwind to underwriting and profits
Similar Companies in Financial Services
Other companies in the same sector with AI ratings